New Blood Test Can Detect Prostate Cancer More Accurately And Earlier – Part 2 of 3
Because a explicit is currently pending, Anson would not list the proteins included in the test. “We are going on to a much more exhaustive follow-on study. At the moment, we are taking over 1,800 samples, which includes 1,200 controls with a sound range of ‘interfering diseases’ that men of 50-plus are prone to and are running a very large analytical validation study”.
That analysis is due to be completed early next year, at which point Oxford is “going to be seeking partnership to cultivate the test further”. He also expressed hope that the technology could one day be applied to other diseases, including lupus, on which there is some preliminary data. Anson predicted that, if further trials go well, the evaluate could be available commercially in 10 to 15 years.
Researchers have been on the hunt for a better screening test for prostate cancer, given the unreliability of the current standard. Because the PSA test generates so many false-positives, many men end up getting surgery or emission that they simply don’t need. “The current PSA test has a great sensitivity, of over 90 percent, but poor specificity, so there are a lot of false-positives. A lot of men are going on for unnecessary diagnostic procedures such as needle biopsies and c radical prostatectomies that aren’t required”.